300223:SZSEIngenic Semiconductor Co., Ltd Class A Analysis
Data as of 2026-06-15 - not real-time
CN¥150.21
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock trades at 150.21 CNY, comfortably above the 20‑day SMA of 146.96 and the 50‑day SMA of 132.73, confirming short‑term strength, while the 200‑day SMA sits at 108.78, underscoring a long‑term bullish backdrop. RSI at 54.5 indicates neutral momentum, but the MACD has turned bearish with a negative histogram, warning of a potential near‑term pullback, and volume is on a decreasing trend, often a precursor to consolidation. The price remains above the technical support of 130.60 and below the resistance near 175.98, leaving room for sideways movement.
Revenue surged 47% year‑over‑year, with a gross margin of 35% and operating margin of 22.9%, reflecting a solid cost structure, and the company holds over 5 billion CNY in cash against negligible debt, delivering a very strong balance sheet. However, ROE is only 5% and ROA 2.5%, indicating modest returns on capital. The trailing P/E of 117x dwarfs the industry average of 37x, and a DCF valuation of roughly 34 CNY suggests a severe overvaluation with upside limited to about 3% while downside risk remains large.
Volatility is high at 79% over the past 30 days and beta below 1 points to pronounced price swings but lower systematic risk. The Fear‑Greed Index reads “Extreme Greed,” hinting that market euphoria may be inflating the price. Dividend yield is a modest 0.1% with a payout ratio under 8%, which is sustainable given the ample cash position. Overall, the stock appears overvalued with limited upside and considerable downside potential.
Revenue surged 47% year‑over‑year, with a gross margin of 35% and operating margin of 22.9%, reflecting a solid cost structure, and the company holds over 5 billion CNY in cash against negligible debt, delivering a very strong balance sheet. However, ROE is only 5% and ROA 2.5%, indicating modest returns on capital. The trailing P/E of 117x dwarfs the industry average of 37x, and a DCF valuation of roughly 34 CNY suggests a severe overvaluation with upside limited to about 3% while downside risk remains large.
Volatility is high at 79% over the past 30 days and beta below 1 points to pronounced price swings but lower systematic risk. The Fear‑Greed Index reads “Extreme Greed,” hinting that market euphoria may be inflating the price. Dividend yield is a modest 0.1% with a payout ratio under 8%, which is sustainable given the ample cash position. Overall, the stock appears overvalued with limited upside and considerable downside potential.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD histogram
- Decreasing volume trend
- Proximity to technical resistance
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Severe overvaluation relative to peers
- Strong cash position and low debt
- Robust revenue growth but modest returns on equity
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Solid balance sheet with ample liquidity
- Industry cyclicality and regulatory environment in China
- Potential for valuation correction as DCF gap narrows
Key Metrics & Analysis
Financial Health
Revenue Growth47.10%
Profit Margin11.86%
P/E Ratio117.4
ROE5.00%
ROA2.48%
Debt/Equity0.12
P/B Ratio5.7
Op. Cash FlowCN¥664.1M
Free Cash FlowCN¥318.8M
Industry P/E36.8
Technical Analysis
TrendBullish
RSI54.5
SupportCN¥130.60
ResistanceCN¥175.98
MA 20CN¥146.96
MA 50CN¥132.73
MA 200CN¥108.78
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair ValueCN¥34.21
Target PriceCN¥155.00
Upside/Downside3.19%
GradeOvervalued
TypeGrowth
Dividend Yield0.10%
Risk Assessment
Beta0.79
Volatility79.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.